- Trials with a EudraCT protocol (113)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
113 result(s) found for: Daratumumab.
Displaying page 1 of 6.
EudraCT Number: 2016-001205-16 | Sponsor Protocol Number: 54767414SMM3001 | Start Date*: 2017-10-18 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma | |||||||||||||
Medical condition: Smoldering multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) HU (Ongoing) ES (Ongoing) NO (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000431-49 | Sponsor Protocol Number: CC220MM002 | Start Date*: 2021-10-18 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with... | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) NO (Ongoing) PT (Ongoing) FI (Ongoing) FR (Ongoing) SE (Ongoing) NL (Ongoing) GR (Ongoing) IE (Ongoing) BE (Ongoing) PL (Ongoing) ES (Ongoing) DK (Ongoing) AT (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001737-27 | Sponsor Protocol Number: 54767414AMY3001 | Start Date*: 2018-04-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnos... | |||||||||||||
Medical condition: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) SE (Ongoing) ES (Ongoing) HU (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) GR (Ongoing) PL (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004683-22 | Sponsor Protocol Number: RGCH005 | Start Date*: 2020-10-16 | |||||||||||
Sponsor Name:Ostfold Hospital Trust | |||||||||||||
Full Title: Daratumumab as a treatment for adult immune thrombocytopenia | |||||||||||||
Medical condition: Immune thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003951-44 | Sponsor Protocol Number: ΕΑΕ-2017/ΜΜ01 | Start Date*: 2017-12-15 | |||||||||||
Sponsor Name:Hellenic Society of Hematology | |||||||||||||
Full Title: A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and /or Refractory Multiple M... | |||||||||||||
Medical condition: Relapsed and /or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002639-48 | Sponsor Protocol Number: 54767414AMY2009 | Start Date*: 2022-07-25 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis | |||||||||||||
Medical condition: Amyloid Light Chain Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) IT (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002272-88 | Sponsor Protocol Number: 54767414MMY3007 | Start Date*: 2014-10-20 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) BE (Completed) ES (Ongoing) CZ (Ongoing) IT (Ongoing) DE (Completed) BG (Completed) RO (Ongoing) PL (Ongoing) HR (Ongoing) GR (Ongoing) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002161-36 | Sponsor Protocol Number: OP-108 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma | |||||||||||||
Medical condition: Patients with relapsed or relapsed-refractory multiple myeloma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) NO (Completed) HU (Completed) FI (Completed) SK (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005139-14 | Sponsor Protocol Number: 54767414SMM2001 | Start Date*: 2015-05-11 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma | |||||||||||||
Medical condition: Smoldering multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Ongoing) CZ (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000752-18 | Sponsor Protocol Number: 54767414MMY2002 | Start Date*: 2013-11-04 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Pro... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000044-22 | Sponsor Protocol Number: C1071005 | Start Date*: 2021-09-14 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALI... | |||||||||||||
Medical condition: MULTIPLE MYELOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) PL (Ongoing) ES (Restarted) IT (Ongoing) DE (Ongoing) CZ (Ongoing) NO (Ongoing) FI (Ongoing) NL (Ongoing) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003377-34 | Sponsor Protocol Number: 54767414ALL2005 | Start Date*: 2018-07-31 | |||||||||||||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||||||||||||
Full Title: An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age With Relapsed/Refractory Precursor B-cell o... | |||||||||||||||||||||||
Medical condition: Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Ongoing) Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004185-34 | Sponsor Protocol Number: 54767414MMY2065 | Start Date*: 2019-05-29 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Mu... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) DK (Completed) NL (Prematurely Ended) FR (Ongoing) ES (Ongoing) PL (Completed) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004076-35 | Sponsor Protocol Number: INCB01158-206 | Start Date*: 2019-08-19 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed or Refractory Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000255-85 | Sponsor Protocol Number: 54767414MMY3004 | Start Date*: 2014-09-24 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) ES (Ongoing) CZ (Ongoing) NL (Completed) HU (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000803-20 | Sponsor Protocol Number: C1071006 | Start Date*: 2022-11-02 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: MAGNETISMM-6: AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENA... | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) ES (Restarted) CZ (Ongoing) BE (Ongoing) DE (Ongoing) FI (Ongoing) HU (Ongoing) FR (Ongoing) GR (Ongoing) DK (Ongoing) AT (Ongoing) IT (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005189-31 | Sponsor Protocol Number: 181114 | Start Date*: 2014-12-16 | |||||||||||
Sponsor Name:Dept Hematology SLB Vejle [...] | |||||||||||||
Full Title: “Monoclonal antibodies for treatment of multiple myeloma. Present status and aspects of effector mechanisms with emphasis on the CD38 antibody daratumumab ”. | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002579-83 | Sponsor Protocol Number: 54767414LUC2001 | Start Date*: 2017-02-24 | ||||||||||||||||
Sponsor Name:Janssen-Cilag International NV | ||||||||||||||||||
Full Title: A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic N... | ||||||||||||||||||
Medical condition: Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) HU (Completed) FR (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002611-34 | Sponsor Protocol Number: 54767414MMY2036 | Start Date*: 2017-10-16 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects ... | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma (MM). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Prematurely Ended) FR (Completed) GR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003253-41 | Sponsor Protocol Number: PMC008 | Start Date*: 2018-09-11 | |||||||||||
Sponsor Name:Polish Myeloma Consortium | |||||||||||||
Full Title: PRE-emptive DAratumumab Therapy Of minimal Residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR). | |||||||||||||
Medical condition: Multiple Myeloma and Minimal Residual Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.